Comparison of FOLH1 target expression to HER‐2, PD‐L1 and PD‐1 expression, suggests that FOLH1 may be a viable therapeutic target for MCC patients, particularly for treatment with antibody‐ or peptide‐based brachytherapy. The gene discussed is FOLH1; the disease is Merkel cell skin cancer.